June 24, 2021
Article
A preview of our August 2021 issue Chairman’s Letter.
The organizations set out 3 recommendations for initial and recurrent C diff treatment.
Video
An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.
Delta Plus is very similar to the Delta variant with 1 additional mutation.
With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.
More treatment options and modalities are now available for patients.
A new report from a Qatari pilot program showed vaccines are highly effective against COVID-19, but they do not completely eliminate risk.
June 23, 2021
The benefits of mRNA vaccinations were determined to still clearly outweigh the risks in adolescents and young adults.
New ASM data show indoor environments are associated with quick and frequent pathogen contamination of the common respiratory device.
Because the number of children hospitalized with COVID-19 is so low, facilities should ensure clinical data is easily available and shared across healthcare platforms.
